Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 7/20 | 0.46 |
| ▸ | MMP2 | P08253 | 6/20 | 0.46 |
| ▸ | MMP3 | P08254 | 4/20 | 0.46 |
| ▸ | MMP8 | P22894 | 5/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | FDPS | P14324 | 6/20 | 0.39 |
| ▸ | LAP3 | P28838 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4305118 | 0.76 | MMP1 (0.44) | MMP1MMP2MMP3MMP8CA12 | |
| SCHEMBL2984368 | 0.75 | MMP1 (0.43) | MMP1MMP2MMP3MMP8CA12 | |
| SCHEMBL1021315 | 0.75 | LMNA (0.38) | MMP1MMP2MMP3MMP8CA12 | |
| SCHEMBL8383247 | 0.74 | MMP2 (0.46) | MMP1MMP2MMP3MMP8CA12 | |
| Phosphoric Acid SCHEMBL28846274 | 0.72 | GABRR1 (0.41) | MMP1MMP2MMP3MMP8CA12 | |
| SCHEMBL3469330 | 0.71 | — | — | |
| SCHEMBL2916525 | 0.69 | MMP2 (0.42) | MMP1MMP2MMP3MMP8CA12 | |
| SCHEMBL15992208 | 0.69 | MMP1 (0.41) | MMP1MMP2MMP3MMP8CA12 | |
| SCHEMBL2990208 | 0.69 | MMP2 (0.42) | MMP1MMP2MMP3MMP8CA12 | |
| Methyl 2-Methylbutanoate SCHEMBL29222980 | 0.69 | MMP1 (0.47) | MMP1MMP2MMP3MMP8CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622847-B2 | Organosilicon compound and dental composition containing same | KURARAY NORITAKE DENTAL INC. (JP) | 2026-05-12 | — | — | US | disclosed |
| US-12214061-B2 | Adhesive composition for dental use | KURARAY NORITAKE DENTAL INC. (JP) | 2025-02-04 | — | — | US | disclosed |
| US-20240164993-A1 | ORGANOSILICON COMPOUND AND DENTAL COMPOSITION CONTAINING SAME | KURARAY NORITAKE DENTAL INC. (JP) | 2024-05-23 | — | — | US | disclosed |
| EP-3782598-B1 | ADHESIVE COMPOSITION FOR DENTAL USE | KURARAY NORITAKE DENTAL INC (JP) | 2023-02-15 | — | — | EP | disclosed |
| US-11304879-B2 | Adhesive composition for dental use | KURARAY NORITAKE DENTAL INC. (JP) | 2022-04-19 | — | — | US | disclosed |
| EP-2070935-A1 | NOVEL COMPOUND, COMPOSITION COMPRISING THE SAME, AND PROCESS FOR PRODUCTION OF POLYMERIZABLE AMIDE | Kuraray Medical Inc. (JP) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12214061-B2 | Adhesive composition for dental use | CDH1, PTK2, H1-0 | MMP1 3328/4885MMP2 3668/4885MMP3 4669/4885 |
| US-11304879-B2 | Adhesive composition for dental use | PTK2, CDH1, ITGA1 | MMP1 2587/4885MMP2 3464/4885MMP3 4377/4885 |
| US-12622847-B2 | Organosilicon compound and dental composition containing same | MSL1, ITGA1, ITGAL | MMP1 1950/4885MMP2 4356/4885MMP3 3507/4885 |
| US-20240164993-A1 | ORGANOSILICON COMPOUND AND DENTAL COMPOSITION CONTAINING SAME | MSL1, ITGA1, ASH2L | MMP1 2234/4885MMP2 4569/4885MMP3 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.